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interleukin-1β; p38 MAPK, p38 mitogen-activated protein kinase; MK2, 
mitogen-activated protein kinase-activated protein kinase 2, RA, 
rheumatoid arthritis; NSAIDS, non-steroidal anti-inflammatory drugs; 
DMARDs, disease-modifying antirheumatic drugs; ELISA, enzyme-linked 




reaction; DMSO, dimethyl sulfoxide; ConA, concanavalin A; TACE; TNF-α-
converting enzyme; BM, bone marrow; M-CSF, macrophage-colony 
stimulating factor; ARE, AU-rich element 
 







Tumor necrosis factor-α (TNF-α) is a major inflammatory cytokine that 
plays an important role in the development of various inflammatory 
diseases. TNF-α has been considered as a potential therapeutic target for 
the treatment of chronic inflammatory diseases, including rheumatoid 
arthritis and inflammatory bowel disease. In this study, we report 
cyclopropyl-{4-[4-(4-fluorophenyl)-2-piperidin-4-yl-thiazol-5-yl]pyrimidin-2-
yl}amine (DBM1285) as a novel inhibitor of TNF-α production. DBM1285 
concentration-dependently inhibited lipopolysaccharide (LPS)-induced 
TNF-α secretion in various cells of macrophage/monocyte lineage, 
including mouse bone marrow macrophages, THP-1 cells and RAW 264.7 
cells. However, LPS-induced mRNA expression of TNF-α was not affected 
by DBM1285 in these cells. Further studies demonstrated that the 
inhibitory effect of DBM1285 on TNF-α production might be mediated by 
post-transcriptional regulation through the modulation of the p38 mitogen-
activated protein kinase (MAPK)/mitogen-activated protein kinase-
activated protein kinase 2 (MK2) signaling pathway. We also confirmed 
that DBM1285 directly inhibits p38 MAPK enzymatic activity. In vivo 
administration of DBM1285 inhibited LPS-induced increase in plasma level 
of TNF-α in mice. Whole blood in vivo target inhibition assay also revealed 
that DBM1285 attenuates p38 MAPK activity after oral administration in 
mice. Moreover, DBM1285 suppressed zymosan-induced inflammation 




suggest that DBM1285 inhibits TNF-α production, at least in part, by 
blocking p38 MAPK/MK2 pathway. Furthermore, in vivo results suggest 
that DBM1285 might be a possible therapeutic candidate for the treatment 







TNF-α is a multifunctional proinflammatory cytokine produced 
mainly by cells of the monocyte/macrophage lineage, which plays an 
important role in chronic inflammatory diseases, such as rheumatoid 
arthritis (RA) and inflammatory bowel disease, by amplifying inflammatory 
signal in multiple pathways (Montecucco and Mach, 2009). Human TNF-α 
is expressed as a 26-kDa protein on the plasma membrane, and is 
cleaved by TNF-α-converting enzyme (TACE) and released as a mature 
17-kDa protein (Palladino et al., 2003). The expression of the TNF-α gene 
is controlled at both the transcriptional and post-transcriptional levels, and 
a variety of signaling pathways are involved in these processes. Mitogen-
activated protein kinases (MAPKs) are a family of serine/threonine kinases 
involved in a variety of cellular processes, such as inflammation, cell 
growth/differentiation and cell survival/death (Chang and Karin, 2001). 
Three kinds of MAPKs, including extracellular signal-regulated kinase, c-
jun N-terminal kinase and p38 MAPK, have been identified so far. Among 
these, p38 MAPK is a key molecule involved in the induction of 
inflammatory genes such as TNF-α, inducible nitric oxide synthase, 
cyclooxygenase-2 and various adhesion molecules (Saklatvala, 2004; 
Schindler et al., 2007). The p38 MAPK is comprised of four different 
isoforms termed p38α, -β, -γ and -δ; p38α is the main isoform involved in 





Among TNF-α-related diseases, RA is one of the most prevalent systemic 
autoimmune disorders (Smolen and Steiner, 2003). It affects about 1% of 
the population and is more frequent in women than in men (Smolen and 
Steiner, 2003; Brennan and McInnes, 2008). Therapeutic approaches for 
RA are divided into two main categories: treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs 
(DMARDs). NSAIDs affect only a small portion of the inflammatory 
cascade such as prostaglandin generation by inhibition of 
cyclooxygenases, and have not been a major treatment option for RA 
patients. Recently, it has been suggested that aggressive treatment with 
DMARDs, rather than NSAIDs, is required for better long-term life quality 
of RA patients by attenuating disease progression and retaining joint 
function. Small molecule DMARDs such as methotrexate and 
sulfasalazine have been used for a long time clinically. Although DMARDs 
remain the most common therapy for RA, they provide only partial clinical 
benefits and cause significant toxicity (Brennan and McInnes, 2008). 
However, the recent development of biological DMARDs targeting tumor 
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) has revolutionized RA 
treatment (Segal et al., 2008). 
 
Although biological DMARDs have proved clinically successful, 
they have innate limitations that include the requirement for injection and 
reduced efficacy after repeated treatment caused by antibody formation 




development of new orally available small molecule DMARDs with 
enhanced efficacy and reduced toxicity is continuously required, and 
numerous small molecule DMARDs targeted for RA treatment are 
currently under development (Pettus and Wurz, 2008; Stanczyk et al., 
2008). To develop a small molecule inhibitor of TNF-α production, we 
screened chemical libraries developed by Dongbu HiTek Co., Ltd. Among 
the chemicals examined, DBM1285 (cyclopropyl-{4-[4-(4-fluorophenyl)-2-
piperidin-4-yl-thiazol-5-yl]pyrimidin-2-yl}amine; Fig. 1) displayed the most 
potent inhibition of TNF-α production in vitro and in vivo. In this study, we 
examined the effect of DBM1285 on lipopolysaccharide (LPS)-induced 
TNF-α production in vitro and in vivo and arthritis progression in an animal 
model of RA. We also elucidated the mechanism responsible for 
DBM1285-mediated inhibition of TNF-α production. Our results implicate 







Chemicals, cells and animals. All reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA) unless otherwise noted. DBM1285 and 
BIRB796 were synthesized and supplied by Dongbu HiTek Co., Ltd. 
DBM1285 is characterized as a small, lipophilic compound with molecular 
weight of 395.5 and cLogP of 3.68 (calculated by ChemBioDraw Ultra 12.0, 
CambridgeSoft, Cambridge, MA, USA). DBM1285 and BIRB796 were 
dissolved in dimethyl sulfoxide (DMSO) and freshly diluted in culture 
medium for in vitro experiments (final DMSO concentration: 0.1%). For in 
vivo experiments, DBM1285 was dissolved in phosphate-buffered saline 
supplemented with 5% Tween 80. 6–8-week-old female C57BL/6 mice and 
Sprague-Dawley (SD) rats were purchased from Koatech (Pyungtaek, 
Gyeonggi, Korea) and cared for as described previously (Kang et al., 
2009). All animals were allowed to acclimate to the local environment for 1 
week. All animal experiments were approved by the Institutional Animal 
Care and Use Committee at the Korea Research Institute of Bioscience 
and Biotechnology. THP-1 cells (TIB-202; American Type Culture 
Collection (ATCC), Manassas, VA, USA) and RAW 264.7 cells (TIB-71, 
ATCC) were grown in RPMI (Invitrogen Life Technologies, Carlsbad, CA, 
USA) and Dulbecco’s modified Eagle’s medium (Invitrogen Life 
Technologies) supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin and 100 μg/ml streptomycin. Bone marrow (BM) macrophages 




BM cells were flushed out from femurs and tibias. After lysing red blood 
cells, whole BM cells (2 x 105 cells/ml) were cultured in 100mm2 culture 
dishes in 10 ml/dish of RPMI complete medium containing 10 ng/ml 
macrophage colony-stimulating factor (M-CSF). On culture day 3, another 
10 ml of fresh RPMI complete medium containing 10 ng/ml M-CSF was 
added, and half of the medium was changed on day 6. On day 8, cells 
were harvested and used as BM macrophages. In general, >90% of cells 
recovered from these cultures were CD11b+ and >95% of cells were 
F4/80+. Cell viability was determined using a Cell Proliferation Kit II 
(Roche Applied Science, Mannheim, Germany) according to 
manufacturer’s instructions. Briefly, the XTT labeling mixture was prepared 
by mixing 50 volumes of 1 mg/ml sodium 3’-[1-(phenylaminocarbonyl)-3,4-
tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate with 1 
volume of 0.383 mg/ml of N-methyldibenzopyrazine methyl sulfate. This 
XTT labeling mixture was added to the cultures and incubated for 2 h at 
37℃. Absorbance was measured at 490 nm with a reference wavelength 
at 650 nm. 
 
Enzyme-linked immunosorbent assay (ELISA) BM macrophages, THP-
1 cells and RAW 264.7 cells were stimulated with LPS (1 μg/ml) for 6 h in 
the presence or absence of DBM1285 (0.001, 0.01, 0.1 or 1 μM) or 
BIRB796 (0.001, 0.01, 0.1 or 1 μM). Culture supernatants were recovered 




DuoSet (for BM macrophages and RAW 264.7 cells; R&D Systems, 
Minneapolis, MN, USA) or human TNF-α DuoSet (for THP-1 cells; R&D 
Systems) according to the manufacturer’s instructions. 
 
Real-time reverse transcription-polymerase chain reaction (RT-PCR) 
The expression of mRNA transcripts was determined by real-time RT-PCR 
as described previously (Han et al., 2007). Total RNAs were isolated using 
TRIzol® Reagent (Invitrogen Life Technologies) as described previously 
(Chomczynski and Mackey, 1995). Equal amounts of RNA were reverse 
transcribed into cDNA using oligo(dT)15 primers. The primer sequences 
used were: mouse TNF-α sense 5’-CCT GTA GCC CAC GTC GTA GC-3’, 
anti-sense 5’-TTG ACC TCA GCG CTG AGT TG-3’; human TNF-α sense 
5’-GAG TGA CAA GCC TGT AGC CCA TGT TGT AGC A-3’, anti-sense 5’-
GGC AAT GAT GAT CCC AAA GTA GAC CTG CCC AGA CT-3’; mouse β-
actin sense 5’-TGG AAT CCT GTG GCA TCC ATG AAA C-3’, anti-sense 
5’-TAA AAC GCA GCT CAG TAA CAG TCC G-3’; human β-actin sense 5’-
GGG TCA GAA GGA TTC CTA TG-3’, anti-sense 5’-GGT CTC AAA CAT 
GAT CTG GG-3’. iQTM SYBR® Green Supermix (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA) and iCycler iQTM Real-time PCR Detection 
System (Bio-Rad Laboratories, Inc.) were used for real-time PCR analysis. 
For amplification, samples were heated to 94°C for 8 min and cycled 45 
times at, 94°C for 30 s, and 56°C for 30 s, and 72°C for 45 s. Using 




the amount of β-actin. 
 
TACE enzyme assay Enzyme assay was performed using recombinant 
human TACE and substrate (MCA-Pro-Leu-Ala-Gln-Ala-Val-DPA-Arg-Ser-
Ser-Ser-Arg-NH2) purchased from R&D Systems. Recombinant human 
TACE (0.01 μg) was loaded in a F16 Black Maxisorp Plate (Nunc, 
Roskilde, Denmark) and DBM1285 (0.001, 0.01, 0.1 or 1 μM) was added 
to each well. Enzyme reaction was started by adding substrate (10 μM) 
and fluorescence was measured at an excitation and emission wavelength 
of 320 nm and 405 nm, respectively, in the kinetic mode. Specific enzyme 
activity was measured according to the manufacturer’s instructions and 
was expressed as the percentage of the vehicle-treated group. 
 
Western Immunoblot analysis Twenty micrograms of whole cell lysates 
were separated by 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and electrotransferred to a nitrocellulose membrane 
(Amersham Bioscience UK, Buckinghamshire, UK). Each membrane was 
preincubated for 1 h at room temperature in Tris-buffered saline, pH 7.6, 
containing 0.05 % Tween 20 and 5 % non-fat milk. Each nitrocellulose 
membrane was incubated with specific antibodies against phospho-p38 
MAP kinase, nonphospho-p38 MAP kinase, phosphor-MAPKAP kinase 2 
(MK2) and nonphospho-MK2 (Cell Signaling Technology, Beverly, MA, 
USA). Immunoreactive bands were then detected by incubating with 




peroxidase and visualizing using enhanced chemiluminescence reagents 
(Amersham Biosciences UK). 
 
Kinase assay Recombinant human p38α MAPK (active), recombinant 
human MK2 (active), recombinant human MK2 (unactive) and MK2 
substrate peptide were purchased from Upstate Biotechnology (Lake 
Placid, NY, USA). Kinase assay was performed according to 
manufacturer’s instructions by serially adding substrate, recombinant 
enzymes, DBM 1285 (0.001, 0.01, 0.1 or 1 μM) and [γ-32P]ATP and 
incubating for 10 min at 30°C. Twenty microliters of reaction product was 
transferred to 2 cm x 2 cm P81 paper (Upstate Biotechnology) and 
washed three times with 0.75 % phosphoric acid. The paper was washed 
once with acetone and subjected to a scintillation counting. 
 
In vivo TNF-α assay Mice were fasted for 24 h before the start of 
experiment. DBM1285 (0.1, 1 or 10 mg/kg) was pretreated by oral 
administration. After 15 min, LPS (2 mg/kg) was intraperitoneally injected 
to each mouse. After 90 min, blood samples were collected by retro-orbital 
puncture and plasmas were prepared. The amount of TNF-α in plasma 
was measured by ELISA as described earlier. 
 
In vivo target inhibition assay The in vivo validation of inhibitory effect of 
DBM1285 on p38 MAPK activity was performed as described previously 




of DBM1285. After 15 min, whole blood was collected in Heparin tubes 
(BD Biosciences, San Jose, CA, USA) by retroorbital puncture. FITC-
conjugated rat anti-mouse Ly-6G (BD Biosciences), APC-conjugated rat 
anti-mouse CD11b (BD Biosciences), and LPS (1 μg/ml) was added into 
the blood and incubated at 37°C for 15 min. 20 volume of BD Phosflow 
Lyse/Fix buffer (BD Biosciences) was added to lyse red blood cells and fix 
white blood cells. Cells were collected by centrifugation and resuspended 
in BD Phosflow Perm Buffer III (BD Biosciences) with anti-phospho-MK2 
(Thr334, Cell Signaling Technology) for intracellular staining of phosphor-
MK2. Cells were collected by centrifugation and finally stained with anti-
rabbit immunoglobulin-PE (BD Biosciences) and incubated at room 
temperature for 30 min. Stained cells were collected and analyzed by flow 
cytometry (FACSCalibur, BD Biosciences). 
 
Zymosan-induced inflammation Inflammation was induced by 
subcutaneous injection of 50 μl of 3 mg/ml Zymosan A isolated from 
Saccharomyces cereviciae (Sigma-Aldrich, St. Louis, MO, USA) into the 
hind footpad of C57BL/6 mice. DBM1285 was orally administered from day 
0 to day 6. On day 7, popliteal lymph nodes were isolated and weighted as 
described previously (Frasnelli et al., 2005). 
 
Adjuvant-induced arthritis Adjuvant-induced arthritis model used was 
reported previously (Ishikawa et al., 2005). Paw volume was measured 1 




injection of 0.5 mg of Mycobacterium tuberculosis (Difco Laboratories, 
Detroit, MI, USA) in 50 μl of mineral oil into the right hind footpad of SD 
rats on day 0. DBM1285 (1, 3 or 10 mg/kg) was orally administrated daily 
from day 0–25. Left hind paw volumes were measured by the water 
displacement method using a model MK-550 plethysmometer (Muramachi 
Kikai, Tokyo, Japan). Changes in paw volume were expressed as percent 
change of initial paw volume of each rat. 
 
Statistical analysis Results are expressed as mean ± S.D. One-way 
ANOVA and Dunnett’s t-test was used for multiple comparisons using 
GraphPad Prism (GraphPad Software; LaJolla, CA, USA). The criterion for 







Effect of DBM1285 on LPS-induced TNF-α secretion in cells of 
macrophage/monocyte lineage. We first examined the effect of 
DBM1285 on LPS-induced TNF-α secretion in various cells, including 
mouse BM macrophages, THP-1 human monocyte cells and RAW 264.7 
mouse macrophage-like cells. As shown in Fig. 2A, DBM1285 
concentration-dependently inhibited LPS-induced TNF-α secretion in BM 
macrophages. Treatment of BM macrophages with 0.01, 0.1 and 1 μM of 
DBM1285 caused 28%, 84% and 100% inhibition of TNF-α secretion, 
respectively. In THP-1 cells and RAW 264.7 cells, DBM1285 also 
suppressed LPS-induced TNF-α secretion in a dose-dependent manner 
(Figs. 2B and 2C). Treatment of cells with 0.01, 0.1 and 1 μM of DBM1285 
inhibited TNF-α secretion in THP-1 cells by 50%, 62% and 84%, 
respectively, and inhibited TNF-α secretion in RAW 264.7 cells by 18%, 
55% and 91%, respectively. IC50 for TNF-α secretion was 0.023 μM, 0.01 
μM and 0.073 μM in BM macrophages, THP-1 cells and RAW 264.7 cells, 
respectively. The concentration and duration of DBM1285 treatment used 
in this study had no significant effect on the viability of BM macrophages, 
THP-1 cells and RAW 264.7 cells (data not shown). In addition, 
concanavalin A (ConA)-induced T cell proliferation and LPS-induced B cell 






Effect of DBM1285 on LPS-induced mRNA expression of TNF-α in BM 
macrophages and THP-1 cells. To investigate whether the DBM1285-
mediated inhibition of TNF-α secretion might be mediated by 
transcriptional regulation of cognate gene, we examined the effect of 
DBM1285 on mRNA expression of TNF-α by real-time RT-PCR. LPS-
induced TNF-α mRNA expression was not affected by DBM1285 treatment 
in BM macrophages (Fig. 3A), THP-1 cells (Fig. 3B) and RAW 264.7 cells 
(Supplmentary Fig. 2). 
 
Effect of DBM1285 on TACE activity. To investigate whether TACE might 
be involved in the inhibitory effect of TNF-α secretion by DBM1285, we 
examined the effect of DBM1285 on TACE activity by performing enzyme 
assay. DBM1285 had no effect on enzymatic activity of TACE (Fig. 4). 
 
Effect of DBM1285 on p38 MAPK activity. It is well-known that the p38 
MAPK/MAPKAP kinase 2 (MK2) signaling pathway is involved in post-
transcriptional regulation of TNF-α biosynthesis by modulation of the 
activity of AU-binding proteins in AU-rich regions of 3’-UTR of TNF-α 
mRNA (Kotlyarov and Gaestel, 2002). Therefore, we examined the effect 
of DBM1285 on LPS-induced phosphorylation of p38 MAPK in BM 
macrophages and THP-1 cells to characterize whether the p38 MAPK 
pathway could be involved in DBM1285-mediated inhibition of TNF-α 
production. DBM1285 blocked LPS-induced phosphorylation of p38 MAPK 




degree of inhibition did not correspond to that of TNF-α secretion. In 
addition, LPS-induced phosphorylation of p38 MAPK was not affected by 
DBM1285 in RAW 264.7 cells (Supplementary Fig. 2). However, 
phosphorylation of MK2, a downstream target of p38 MAPK and a 
regulator of TNF-α biosynthesis, was dramatically suppressed by 
DBM1285 treatment in LPS-stimulated BM macrophages (Fig. 5C). To 
further characterize the molecular target of DBM1285, we examined the 
effect of DBM1285 on kinase activity of p38 MAPK and MK2 by in vitro 
enzyme assay. DBM1285 potently suppressed kinase activity of p38 
MAPK (Figs. 6A and 6B). However, MK2 activity was not affected by 
DBM1285 treatment (Fig. 6C). 
 
To compare the potency and mode of action of DBM1285 with a 
previously reported p38 MAPK inhibitor, we examined the effect of 
BIRB796 (Regan et al., 2003) on LPS-induced TNF-α secretion, TNF-α 
mRNA expression and p38 MAPK phosphorylation. As shown in Fig. 7A, 
BIRB796 also suppressed TNF-α secretion in a concentration-dependent 
manner in our system. Consistent with the result obtained using DBM1285, 
BIRB796 treatment also had no effect on LPS-induced mRNA expression 
of TNF-α (Fig. 7B). However, BIRB796 potently suppressed LPS-induced 
phosphorylation of p38 MAPK (Fig. 7C) and MK2 (Supplementary Fig. 3). 
 
Inhibition of LPS-induced TNF-α production and validation of p38 




investigate whether DBM1285 could also exert its effect in vivo, we first 
examined the effect of DBM1285 on LPS-induced TNF-α production in 
mice. As shown in Fig. 8A, oral administration of DBM1285 suppressed 
LPS-induced increase in serum level of TNF-α in a dose-related manner. 
To further confirm the inhibition of p38 MAPK in vivo by DBM1285 
treatment, we treated mice with DBM1285 for 15 min and analyzed p38 
MAPK activity by measuring intracellular MK2 phosphorylation in 
monocyte population of whole blood cells. As shown in Fig. 8B, MK2 
phosphorylation was detected in LPS-treated samples. However, 
DBM1285 treatment markedly suppressed phosphorylation of MK2 by LPS 
treatment (Fig. 8B). 
 
Effect of DBM1285 on zymosan-induced inflammation and adjuvant-
induced arthritis in murine models. We investigated the effect of 
DBM1285 in zymosan-induced inflammation model. Popliteal lymph node 
weight was substantially increased in vehicle-treated mice and this was 
suppressed by oral administration of DBM1285 in a concentration-
dependent manner (Fig. 9A). In addition, we also demonstrated that 
DBM1285 potently suppressed plasma level of TNF-α in zymosan-treated 
mice (Fig. 9B). Moreover, we examined the effect of DBM1285 on RA 
development in an adjuvant-induced arthritis model. Rats were injected 
subcutaneously with adjuvant in right rear feet on day 0 and disease 
progression was monitored in the left rear feet for 26 days. Vehicle-treated 




increased to 280.4% of initial volume at day 18 and gradually decreased 
thereafter (Fig. 9C). However, daily oral administration of 10 mg/kg of 
DBM1285 caused 49% inhibition at day 18 and 41% inhibition at day 26 
(Fig. 8C). Body weights of DBM1285-treated rats were not significantly 
decreased compared to that of vehicle-treated rats during experiment and 
LD50 was estimated over 300 mg/kg according to single and 14-day 








The results of the present study support the potential of DBM1285 
as an inhibitor of TNF-α production and as a therapeutic candidate for 
TNF-α-related diseases. Here, we have shown that DBM1285 significantly 
inhibits LPS-induced secretion of TNF-α in mouse and human cells of 
macrophage/monocyte lineage, including mouse BM macrophages, THP-1 
cells and RAW 264.7 cells. Our results also demonstrate that although 
submicromolar concentrations of DBM1285 can markedly suppress TNF-α 
secretion in LPS-stimulated cells of macrophage/monocyte lineage, 
treatment with 10 μM of DBM1285 has no effect in ConA-induced T cell 
proliferation and LPS-induced B cell proliferation, suggesting that the 
effect of DBM1285 might be cell type-specific. In general, high specificity is 
associated with reduced adverse effect. Therefore, it is assumed that 
DBM1285 might be a good therapeutic candidate for TNF-α-related 
diseases. It is noteworthy that DBM1285 was active in animals following 
oral administration. In vivo administration of DBM1285 resulted in a 
decrease in LPS-induced serum level of TNF-α in mice. Moreover, daily 
oral administration of DBM1285 also suppressed RA progression in an 
adjuvant-induced arthritis model. Collectively, our results suggest that 
DBM1285 is an orally available therapeutic candidate for RA and the anti-
arthritic activity of DBM1285 might be mediated by blocking TNF-α 





To investigate the mechanism responsible for the inhibitory effect 
of DBM1285 on TNF-α secretion, we first analyzed the effect of DBM1285 
on LPS-induced mRNA expression of TNF-α gene. In contrast to the 
results of TNF-α secretion, DBM1285 did not affect TNF-α mRNA 
expression in LPS-stimulated BM macrophages, THP-1 cells and RAW 
264.7 cells, suggesting that the inhibitory effect of DBM1285 on TNF-α 
secretion is not mediated at the transcriptional level. It is well-known that 
the expression of TNF-α is controlled at both the transcriptional and post-
transcriptional level (Kumar et al., 2003). Because DBM1285 does not 
affect the transcriptional regulation of TNF-α, we searched targets involved 
in post-transcriptional regulation of TNF-α. TACE is one of the most well-
known molecular targets that regulate TNF-α secretion post-
transcriptionally (DasGupta et al., 2009). It mediates proteolytic cleavage 
of membrane-bound form of TNF-α resulting in secretion of active soluble 
form of TNF-α (Black, 2002). Therefore, we assessed the possibility 
whether DBM1285 exerts its inhibitory effect on TNF-α secretion by 
blocking TACE activity. Our observation that DBM1285 had no effect on 
TACE activity suggests that TACE is not a target of DBM1285. 
 
p38 MAPK plays an important role in cellular responses to external 
stress signals (Schett et al., 2008) and is implicated in the expression of 
inflammatory mediators; inhibitors of p38 MAPK exert anti-inflammatory 
effect in various preclinical animal models (Kumar et al., 2003). Although a 




inhibitors of p38 MAPK such as BMS-582949 (Phase II) and SCIO-469 
(Phase II) are still in clinical trials for RA treatment. MK2 is a downstream 
target of p38 MAPK that is essential for LPS-induced TNF-α biosynthesis 
(Kotlyarov et al., 1999). Furthermore, the major post-transcriptional effects 
of p38 MAPK are mediated by MK2 (Kotlyarov and Gaestel, 2002). MK2 
regulates stability and translational efficacy of AU-rich elements (ARE)-
containing genes in their 3’UTR by direct phosphorylation of ARE-binding 
proteins (Kumar et al., 2003). In fact, it has been reported that MK2 
regulates biosynthesis of TNF-α through ARE-dependent modulation of 
translational efficiency (Tietz et al., 2006). Therefore, we hypothesized that 
p38 MAPK/MK2 signaling pathway might be involved in the inhibitory 
effect of DBM1285 on TNF-α secretion. To test this hypothesis, we first 
examined the effect of DBM1285 on the phosphorylation of p38 MAPK. 
Our results showed that DBM1285 slightly blocked LPS-induced 
phosphorylation of p38 MAPK in BM macrophages and THP-1 cells. 
Although DBM1285 suppressed the phosphorylation of p38 MAPK, the 
potency of DBM1285 on p38 MAPK phosphorylation did not correspond to 
that on TNF-α secretion. Therefore, we examined the effect of DBM1285 
on MK-2 phosphorylation in LPS-stimulated BM macrophages and 
demonstrated that DBM1285 potently inhibited LPS-induced MK2 
phosphorylation. These results suggest that DBM1285 blocks the activity 
of p38 MAPK, although its effect on p38 MAPK phosphorylation is minimal. 
We further confirmed by kinase assay that DBM1285 suppresses 




of MK2, but not MK2 activity itself. We also confirmed the inhibition of p38 
MAPK activity by DBM1285 treatment in vivo by whole blood in vivo target 
inhibition assay. Collectively, these results suggest that DBM1285 directly 
binds to p38 MAPK resulting in blockade of downstream signaling cascade 
both in vitro and in vivo. 
 
BIRB796 is a well-known inhibitor of p38 MAPK (Kumar et al., 
2003). To compare the potency and mode of action of DBM1285 with 
those of BIRB796, we examined the effect of BIRB796 on LPS-induced 
TNF-α expression and p38 MAPK phosphorylation. Our results showed 
that BIRB796 dose-dependently suppressed LPS-induced secretion of 
TNF-α. It was also demonstrated that the potency of DBM1285 on 
inhibition of TNF-α secretion was comparable to or better than that of 
BIRB796. As in the case of DBM1285, BIRB796 did not affect LPS-
induced mRNA expression of TNF-α, suggesting that BIRB796 might also 
regulate TNF-α secretion at post-transcriptional level. However, analysis of 
the effect of BIRB796 on p38 MAPK phosphorylation revealed a dramatic 
inhibition of LPS-induced phosphorylation of p38 MAPK. This result is 
different from that obtained with DBM1285, which showed slight inhibition 
of p38 MAPK phosphorylation and suggests that these two compounds do 
not share the same mechanism to regulate the activity of p38 MAPK. A 
previous report described that BIRB796 inhibited p38 MAPK activity 
through direct binding (Regan et al., 2003). From these results, we can 




exert their inhibitory effect, but their binding sites and exact inhibitory 
mechanisms are different (Fig. 10), though further studies are required to 
fully address this question. 
 
In summary, the results presented in this report demonstrate that 
DBM1285 inhibits TNF-α production in vitro and in vivo and exerts an anti-
arthritic effect in an animal model. We also show that the inhibitory effect 
of DBM1285 on TNF-α production is mediated by inhibition of p38 MAPK 
activity and the downstream signaling cascade. Our results implicate 
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Legends for figures 
 
Fig. 1. Chemical structure of DBM1285. 
 
Fig. 2. Effect of DBM1285 on LPS-induced TNF-α secretion. Mouse BM 
macrophages (A), THP-1 cells (B) and RAW264.7 cells (C) were 
pretreated with vehicle (VH; DMSO) or indicated concentrations of 
DBM1285 for 1 h before being incubated with LPS (1 μg/ml) for 6 h. The 
culture supernatants were subsequently isolated and analyzed for TNF-α 
secretion by ELISA. Each column shows the mean ± S.D. of triplicate 
determinations. Statistical significance was determined using Dunnett’s t-
test versus vehicle-treated group (*p < 0.05). 
 
Fig. 3. Effect of DBM1285 on LPS-induced TNF-α mRNA expression. 
Mouse BM macrophages (A) and THP-1 (B) cells were pretreated with 
vehicle (VH: DMSO) or indicated concentrations of DBM1285 for 1 h 
before being incubated with LPS (1 μg/ml) for 6 h. Total RNAs were 
isolated and the mRNA expression of TNF-α and β-actin was determined 
by real-time RT-PCR. The amount of TNF-α mRNA was normalized by that 
of β-actin and expressed as fold induction versus untreated group. Each 
column shows the mean ± S.D. of triplicate determinations. Statistical 
significance was determined using Dunnett’s t-test versus vehicle-treated 





Fig. 4. Effect of DBM1285 on TACE enzyme activity. Recombinant human 
TACE was treated with vehicle (VH: DMSO) or indicated concentrations of 
DBM1285. TACE enzyme activity was measured as described in Materials 
and Methods by measuring fluorescence signal. Each column shows the 
mean ± S.D. of triplicate determinations. 
 
Fig. 5. Effect of DBM1285 on LPS-induced phosphorylation of p38 MAPK 
and MK-2. Mouse BM macrophages (A, C) and THP-1 cells (B) were 
pretreated with vehicle (VH: DMSO) or indicated concentrations of 
DBM1285 for 1 h before being incubated with LPS (1 μg/ml) for 30 min. 
Cells were lysed and phosphorylated and non-phosphorylated forms of 
p38 MAPK (A, B) and MK2 (C) were detected by Western immunoblot 
analysis. 
 
Fig. 6. Effect of DBM1285 on p38 MAPK and MK2 kinase activity. (A) 
Active human p38 MAPK was treated with vehicle (VH: DMSO) or 
indicated concentrations of DBM1285. ATF-2 and [γ-32p]ATP was added 
and incubated for 10 min at 30°C. (B) Active human p38 MAPK was 
treated with vehicle (VH: DMSO) or indicated concentrations of DBM1285. 
Unactive MK2 and ATP was added and incubated for 15 min at 30°C. 
Subsequent reaction was started by adding MK2 substrate peptide and [γ-
32p]ATP and reaction mixture was incubated for 10 min at 30°C. (C) Active 
human MK2 was treated with vehicle (VH: DMSO) or indicated 




added and incubated for 10 min at 30°C. Final reaction mixtures were 
transferred to P81 paper and radiolabeled substrates were detected by 
scintillation counting. Each column shows the mean ± S.D. of triplicate 
determinations. Statistical significance was determined using Dunnett’s t-
test versus vehicle-treated group (*p < 0.05). 
 
Fig. 7. Effect of BIRB796 on LPS-induced TNF-α secretion, TNF-α mRNA 
expression and p38 MAPK phosphorylation. THP-1 cells were pretreated 
with vehicle (VH: DMSO) or indicated concentrations of BIRB796 for 1 h 
before being incubated with LPS (1 μg/ml) for 6 h for measurement of 
TNF-α secretion and TNF-α mRNA expression and 30 min for 
measurement of p38 MAPK phosphorylation. (A) The culture supernatants 
were subsequently isolated and analyzed for TNF-α secretion by ELISA. 
Each column shows the mean ± S.D. of triplicate determinations. (B) Total 
RNAs were isolated and the mRNA expression of TNF-α and β-actin was 
determined by real-time RT-PCR. The amount of TNF-α mRNA was 
normalized by that of β-actin and expressed as fold induction versus 
untreated group. (C) Cells were lysed and phosphorylated and non-
phosphorylated forms of p38 MAPK were detected by Western 
immunoblot analysis. Statistical significance was determined using 
Dunnett’s t-test versus vehicle-treated group (*p < 0.05). 
 
Fig. 8. Effect of DBM1285 on TNF-α production and p38 MAPK activity in 




PBS) or indicated concentrations of DBM1285 for 15 min and LPS (2 
mg/kg) was injected intraperitoneally to each mouse. After 90 min, blood 
samples were collected, plasmas were prepared and TNF-α level was 
determined by ELISA. Each column shows the mean ± S.D. of triplicate 
determinations. Statistical significance was determined using Dunnett’s t-
test versus vehicle-treated group (*p < 0.05). (B) Mice were pretreated 
with vehicle (VH: 5% Twee 80 in PBS) or 10 mg/kg of DBM1285 for 15 min. 
Whole blood was collected and stimulated with 1 μg/ml of LPS for 15 min. 
Monocytes (CD11bMedLy-6G-) in whole blood cells were analyzed for MK2 
phosphorylation by flow cytometry. 
 
Fig. 9. Effect of DBM1285 on zymosan-induced inflammation and 
adjuvant-induced arthritis in murine models. (A) Inflammation was induced 
by subcutaneous injection of zymosan A (150 μg/mouse). Vehicle (VH: 5% 
Tween 80 in PBS) or indicated concentrations of DBM1285 were treated 
daily by oral administration. On day 7, popliteal lymph nodes were isolated 
and weighed. Data were expressed as the mean ± S.D. of quadruplicate 
determinations. (B) Mice were pretreated orally with vehicle (VH: 5% 
Tween 80 in PBS) or indicated concentrations of DBM1285 for 15 min and 
zymosan A (10 mg/mouse) was injected intraperitoneally to each mouse. 
After 90 min, blood samples were collected, plasmas were prepared and 
TNF-α level was determined by ELISA. Each column shows the mean ± 
S.D. of triplicate determinations. (C) Arthritis was induced by 




Tween 80 in PBS) or 10 mg/kg or DBM1285 was treated daily by oral 
administration. Changes in paw volume were measured using 
plethysmometer. Data were expressed as the mean ± S.D. of seven 
determinations. Statistical significance was determined using Dunnett’s t-
test versus vehicle-treated group (*p < 0.05). 
 
Fig. 10. Schematic diagram showing mode of action of DBM1285 on TNF-
α production. (A) The p38 MAPK/MK2 pathway is implicated in the post-
transcriptional regulation of TNF-α gene. DBM1285 and BIRB796 inhibit 
MK2 phosphorylation and activation by p38 MAPK through the modulation 
of p38 MAPK activity. (B) Differential mode of action of DBM1285 and 
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